Not a good buy right now: trend is bearish (SMA_200 > SMA_20 > SMA_5) and momentum is still deteriorating (MACD histogram negative and expanding).
Price (~0.58 pre-market) is sitting right on/just below key support (S1 ~0.586). Without a catalyst or confirmed reversal signal, support can fail.
No event-driven tailwinds: no notable news in the past week, and hedge fund/insider activity is neutral.
Fundamentals are not improving (2025/Q3 revenue slightly down YoY; losses and EPS deterioration), making a momentum/reversal buy unattractive for an impatient buyer.
Momentum: MACD histogram -0.00974 (below 0) and negatively expanding → downside momentum is strengthening, not stabilizing.
RSI: RSI_6 = 29.223 (near oversold). This can support a short-term bounce, but on its own is not a buy trigger while MACD is worsening.
Key levels: Pivot 0.747 (well above current price, acts as reclaim level). Support S1 0.586 and S2 0.487; resistance R1 0.907 and R2 1.006.
Pattern-based expectation (similar candlesticks): modest expected moves (next day ~-0.29%, next week ~+0.77%, next month ~+0.09%), suggesting limited upside edge right now.
Positive Catalysts
Gross margin improved in 2025/Q3 (82.74%, +0.18% YoY), showing product economics may be resilient.
RSI near oversold levels can sometimes precede a short-term technical bounce if buyers step in at support.
No significant hedge fund or insider selling pressure indicated (both neutral).
Neutral/Negative Catalysts
Congress/politician activity: no recent congress trading data available (no external “influential buyer” signal).
Financial Performance
Latest quarter: 2025/Q3.
Revenue: $3.083M, down -0.80% YoY (no growth traction).
Net income: -$9.502M, down -3.57% YoY (losses deepening).
EPS: -6.28, down -76.11% YoY (material deterioration).
Gross margin: 82.74%, up +0.18% YoY (small improvement, but not translating into bottom-line improvement).
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
No analyst rating or price target change data provided, so there is no visible recent Wall Street upgrade/downgrade trend to support a buy.
Wall Street pros (based on available data): none clearly identifiable from ratings/targets here.
Wall Street cons (based on available data): lack of supportive analyst momentum/price target raises, combined with deteriorating earnings profile, offers little institutional-style validation for an immediate buy.
Wall Street analysts forecast JAGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAGX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
Analyst Rating
0
Wall Street analysts forecast JAGX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for JAGX is 0 USD with a low forecast of 0 USD and a high forecast of 0 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
